Test compounds 6a-h in general exhibited dose dependent increase in anticancer activity in the cell lines but were less potent than adriamycin. Amongst the test compounds, 6e was most active with IC 50 values of <15 μM in two cell lines tested, while in remaining three cell lines its IC 50 values were in the range of 27-53 μM. Adriamycin had IC 50 values of < 15 μM concentration. Adriamycin (doxorubicin) does not act by inhibiting FPT, but by interacting with DNA by intercalation [9] . Hence it was not used as a standard in the FPT inhibition study.
Test compounds 6a-h exhibited potent FPT inhibitory activity at the doses studied and had IC 50 values in the range of 32-40 μM except for 6f which had IC 50 of 55 μM. In comparison, des loratadine had IC 50 of 60 μM and 10-bromodesloratadine had IC 50 of 53 μM. 10-bromodesloratadine was evaluated to examine the effect of introduction of bromine in desloratadine. The results show that 10-bromodesloratadine was more potent compared to desloratadine indicating that activity increases with bromination at C 10 position.
It is clear that test compounds 6a-h in general are more potent than 10-bromodesloratadine and this enhanced activity can be attributed to the presence of zinc binding groups in these molecules. -dimethoxy-2H-3-benzazepin-2-one hydrochloride is a new bradycardiac agent. Its activity is a result of a direct effect on the sinus node, reducing the slope of the spontaneous diastolic depolarization. It is a selective sinus node I f inhibitor used in the treatment of angina pectoris in patients unable to take beta blockers [1] [2] [3] [4] [5] . Literature survey revealed that, analytical methods like LC with fl uorescence detector and LC with tandem mass spectrometric detector for determination of ivabradine in biological samples were reported [6] [7] [8] [9] .
However, till date no assay procedure has been reported for the determination of this drug in bulk and pharmaceutical formulations. Hence there is a need to develop a simple assay procedure for the determination of this drug in tablet formulations. Owing to the wide spread use of HPLC in routine analysis, it is important that well validated HPLC method has to be developed for estimating ivabradine hydrochloride. The aim of this study is development of a simple, precise, rapid and accurate reverse phase HPLC method for estimation of ivabradine hydrochloride in pharmaceutical formulations as per ICH guidelines which is easily adaptable as a routine in quality testing laboratories in industry and academic institutes [10] .
The pure sample of ivabradine hydrochloride used in the development of this analytical method was gifted by Ind-Swift Labs, Jammu, India. Methanol and water were of HPLC grade (Merck India Ltd., Mumbai, india). All other reagents were of AR grade and were purchased from Merck Chemicals, India. Commercially available Ivabrad and Inapure tablets, claimed to contain 7.5 mg and 5 mg ivabradine, respectively were procured from local Pharmacy.
An isocratic HPLC with two Waters 515 HPLC pump, Waters Inline Degasser AF, 717 plus Auto sampler, 2998 PDA Detector and RP C18 Column (SS Wakosil C18AR, 250×4.6 mm, packed with 5 μm particle size) was used. The HPLC system was equipped with Empower software. For HPLC, the mobile phase used was a mixture of methanol and phosphate buffer (pH 6.5) in the ratio of 60:40 v/v; it was fi ltered before use through a 0.22 μm membrane fi lter in a Millipore fi ltration assembly and pumped from the respective solvent reservoirs to the column at a fl ow rate of 0.8 ml/min. The run time was set at 10 min and column was maintained at ambient temperature. The volume of injection is 10 μl. Prior to the injection of drug solutions, the column was equilibrated for at least 30 min with the mobile phase flowing through the system. The eluent was monitored at 285 nm and data acquired was stored and analyzed with the software.
A standard stock solution of ivabradine hydrochloride (1 mg/ml) was prepared in HPLC grade water. To study the linearity range of the drug, serial dilutions were made from standard stock solution in the range of 30-210 μg/ml with HPLC grade water. Each of these drug solutions (10 μl) was injected, into the HPLC system to obtain the chromatogram. From these, the area under the peak of the drug was noted and the data of peak area plotted against the corresponding concentrations were treated by linear least-square regression analysis.
For intraday assay precision, the sample injection and measurement of peak areas were carried out 3 times with in a day by using three different concentrations of 90, 120 and 150 μg/ml and were expressed in terms of % RSD. For interday assay precision, the sample injection and measurement of peak areas were carried out 3 times for 3 days by using the same concentrations as that of intra day assay precision, and were expressed in terms of % RSD. By introducing slight changes in organic phase of mobile phase composition (±2 %), pH (±0.2), fl ow rate (±0.1 ml/min) and the wavelength (±1 nm), the effects of the results were examined.
Recovery studies was confi rmed by standard addition method and were carried out by applying the method to pre analyzed samples to which known amount of standard drug corresponding to 12, 24 and 36 μg/ ml was spiked. At each level of the amount, three determinations were performed. This was done to check for the recovery of the drug at different levels in the formulations.
Lactose, talc, starch, magnesium stearate and microcrystalline cellulose were added as excipients to three different concentrations of 90, 120 and 150 μg/ ml of standard ivabradine hydrochloride solutions and analyzed by the proposed method. Paired t-Test was applied to compare the results.
After equilibration of column with mobile phase, the chromatograms were recorded and peak response i.e., peak area was measured for a concentration of 120 μg/ml. Other parameters like tailing factor, capacity factor, number of theoretical plates were calculated and compared with standard values.
Twenty tablets containing Ivabradine hydrochloride as the active ingredient were weighed and their average weight was calculated. Tablets were then crushed and powdered in a mortar and pestle. A portion of the powder equivalent to 25 mg of the drug (on the label claim basis) was transferred to a 25 ml volumetric flask. The drug was dissolved in by adding 10 ml of HPLC grade water to the fl ask with constant stirring for 15-20 min on a magnetic stirrer. The volume was made up to the mark with HPLC grade water to prepare stock solution of 1 mg/ml. The resulting solution was centrifuged at 3000 rpm for 5 min and then filtered through 0.45 μ nylon syringe filter and the filtrate was further diluted to give the concentration of 120 μg/ml and then analyzed by the proposed method. The analysis was carried out for 6 times and the mean peak area of six such determinations was calculated. The same procedure was used to estimate the content of the drug in both the brands Ivabrad 7.5 mg and Inapure 5 mg, respectively.
To achieve sharp peak under isocratic conditions, mixtures of methanol and phosphate buffer in different combinations were tried as mobile phase on a C18 stationary phase. A binary mixture of methanol and phosphate buffer (pH 6.5) in 60:40 v/v proportions was proved to be the most suitable of all combinations since chromatographic peak was better defi ned and free from tailing with this system. Under the above-mentioned chromatographic conditions, the retention time of 6.55±0.05 min (fi g.1) was obtained for ivabradine hydrochloride.
The linear regression data for the calibration curves (n=4) showed a good linear relationship over concentration range 30-210 μg/ml with respect to the peak area as depicted in Table 1 . The intraday precision and interday precision were expressed in terms of % RSD and found below 0.86 and 0.53, respectively. The results of intra and interday variation of Ivabradine hydrochloride at three different concentrations levels of 90, 120 and 150 μg/ml are depicted in Table 2 .
The method was found to be robust for slight changes in the organic phase of mobile phase composition (±2 %), pH (±0.2), flow rate (±0.1 ml/min) and the wavelength (±1 nm) during the development of the method. The proposed method when used for extraction and subsequent estimation of ivabradine hydrochloride from pharmaceutical dosage forms after spiking with 12, 24 and 36 μg/ml of additional drug afforded mean % recovery of 99.00 and 98.55 for Ivabrad and Inapure tablets respectively as depicted in Table 3 .
The absence of interfering peaks in the chromatogram suggests that the tablet excipients do not interfere with the estimation of the drug by the proposed HPLC method. Paired t-Test was applied to compare the results as depicted in Table 4 . The system suitability parameters when compared to the standard values are within the limit. A single chromatogram was observed in the chromatogram of the drug samples from tablets. There was no interference from the excipients commonly present in the tablets. The drug content was found to be 99.38%±0.68 with a % RSD of 0.57 and 99.29±0.47 with a % RSD of 0.39 for Ivabrad (7.5 mg) and Inapure (5 mg) tablets, respectively.
The developed RP-HPLC method provides a convenient and effi cient method for the estimation of Ivabradine hydrochloride in dosage form. There was no interference from the excipients used in the tablet formulation and hence the method is suitable for analysis of tablets. The results of validation showed that the proposed method is simple, linear, precise, accurate and selective and is employed in routine assay of ivabradine hydrochloride in tablets. Satranidazole, 1-methylsulphonyl-3-(1-methyl-5-nitro-2-imidazolyl)-2-imidazolidinone, is one of the large series of nitroimidazoles with potent antiprotozoal activity against E. hystolytica, T.vaginalis and giardia [1] . It is not offi cial as yet in IP, USP and BP [2, 3] . Though the molecule is found to be effective against these microorganisms, its therapeutic efficacy is hindered due to its poor aqueous solubility [4] . The poor aqueous solubility and wettability of satranidazole gives rise to diffi culties in pharmaceutical formulations meant for oral or parenteral use, which may lead to variation in bioavailability [5] . Co-solvency is one of the methods to improve solubility especially in case of liquid formulations. The choice of the appropriate co-solvent is important to obtain maximum solubility of drug [6] . Evaluation of solubility parameter in different solvent blends of various polarities would provide important insight about the solubility of drug. Solubility parameter () is an intrinsic physicochemical property that infl uences structure activity and transport kinetics of a drug substance [7] . Literature survey revealed that solubility parameter of satranidazole is not estimated by any method till date. So the present study attempts to determine the solubility parameter of satranidazole in different blends of dioxane-water. Experimental values obtained were compared with the theoretical values obtained by molar volume method and Fedor's group substitution method [8] . Dioxane and water were selected based on their Hildebrand values. Water and dioxane exhibit extremities of polarity [9] .
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